Skip to content

Study · Systematic review · 2009

5 results

[Evaluation of efficacy of thymosin alpha1 in the treatment of sepsis: a systematic review].

Yu Y, Tian JH, Yang KH, Zhang P

Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue1 Jan 2009Cited by 4 (Europe PMC)

PMID19141185 (opens in a new tab)PepBankPUB-19141185
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of five trials in sepsis, thymosin alpha1 may raise the level of CD4+ T lymphocytes (WMD 6.24).

    In plain wordsIn a review of trials in sepsis, thymosin alpha1 may raise CD4+ T cell levels.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+ T lymphocyte level
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    WMD
    6.24 NA
    CD4+ T lymphocytes

    Source sentences

    Summary
    Meta-analysis showed that thymosin alpha1 may raise the level of CD4(+)T lymphocytes [WMD=6.24, 95% confidence interval (CI) 1.12 to 11.36]
    1 context sentence
    Summary · context
    Five randomized controlled trials (198 patients) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of five trials in sepsis, thymosin alpha1 may raise the CD4+/CD8+ ratio (WMD 0.14).

    In plain wordsIn a review of trials in sepsis, thymosin alpha1 may raise the CD4+/CD8+ T cell ratio.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+/CD8+ ratio
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    WMD
    0.14 NA
    CD4+/CD8+ ratio

    Source sentences

    Summary
    and the ratio of CD4(+)/CD8(+)(WMD=0.14, 95%CI 0.03 to 0.25, P=0.01)
    1 context sentence
    Summary · context
    Five randomized controlled trials (198 patients) were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In a meta-analysis of five trials in sepsis, thymosin alpha1 decreased the APACHE II score (WMD 3.82).

    In plain wordsIn a review of trials in sepsis, thymosin alpha1 lowered the APACHE II illness severity score.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseAPACHE II score
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    Dose not stated

    Measurements

    WMD
    3.82 NA
    APACHE II score

    Source sentences

    Summary
    Also, thymosin alpha1 therapy decreased the score of acute physiology and chronic health evaluation II (APACHE II), WMD=3.82, 95%CI 2.36 to 5.28 , P<0.001 )
    1 context sentence
    Summary · context
    Five randomized controlled trials (198 patients) were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In a meta-analysis of five trials in sepsis, thymosin alpha1 reduced the days of mechanical ventilation (WMD -4.17).

    In plain wordsIn a review of trials in sepsis, thymosin alpha1 shortened the time on a ventilator.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseMechanical ventilation days
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    Dose not stated

    Measurements

    WMD
    −4.17 NA
    mechanical ventilation days

    Source sentences

    Summary
    and the mechanical ventilation days (WMD=-4.17, 95%CI-7.00 to -1.34, P=0.004 ).
    1 context sentence
    Summary · context
    Five randomized controlled trials (198 patients) were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In a meta-analysis of five trials in sepsis, thymosin alpha1 shortened the duration of intensive care unit stay (WMD -4.87).

    In plain wordsIn a review of trials in sepsis, thymosin alpha1 shortened the stay in intensive care.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseICU stay duration
    Study

    n: not reported in source

    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    Dose not stated

    Measurements

    WMD
    −4.87 NA
    ICU stay

    Source sentences

    Summary
    Furthermore, thymosin alpha1 therapy shortened the duration of intensive care unit (ICU) stay (WMD=-4.87, 95%CI -8.17 to -1.60, P=0.004).
    1 context sentence
    Summary · context
    Five randomized controlled trials (198 patients) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.